OPM-101
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Melanoma
Conditions
Advanced Melanoma
Trial Timeline
Sep 1, 2025 → Dec 1, 2027
NCT ID
NCT07040436About OPM-101
OPM-101 is a phase 1/2 stage product being developed by Oncodesign Precision Medicine for Advanced Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07040436. Target conditions include Advanced Melanoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Melanoma were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07040436 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Advanced Melanoma